Placenta-derived multipotent stem cells
View Patent ↗This disclosure provides isolated cells and compositions comprising one or more isolated cell(s) as described herein. In one aspect, the isolated cell is a pre-term placenta-derived stem cell (also referred to placenta-derived multi potent stem cells (pmSCs). As used herein, the term “pre-term placenta-derived multipotent stem cell or placenta-derived stem cells” intends a cell isolated from placental tissue prior to delivery of the fetus by surgery or birth. In another aspect, the isolated cell is a chorionic villus (CV)-derived multipotent placental stem cells (C-mpSCs). Also provided are compositions comprising these cells, wherein the composition comprises an effective amount of the isolated cells as described herein.
1. A method for treating spina bifida in a subject in need thereof comprising administering to the subject an effective amount of an isolated pre-term placenta-derived multipotent stem cell or cells (PMSCs) or culture conditioned media therefrom.
2. The method of claim 1 , wherein the PMSCs comprise chorionic villus (CV)-derived multipotent stem cells (C-mpSCs).
3. The method of claim 1 , wherein the PMSCs or the culture conditioned media therefrom are administered in a pharmaceutically acceptable carrier or a biocompatible matrix.
4. The method of claim 1 or 3 , wherein the subject is a fetus and the PMSCs or the culture conditioned media therefrom is administered to the fetus in utero.
5. The method of claim 1 , wherein said PMSCs express one or both markers of CD56 + or CD271 + .
6. The method of claim 5 , wherein said PMSCs express one or more markers of CD105 + , CD90 + , CD73 + , CD44 + or CD29 + .
7. The method of claim 5 , wherein said PMSCs express the marker CD184 + .
8. The method of claim 1 , wherein said PMSCs express an integrin receptor comprising one or both of CD49d or CD49f.
9. The method of claim 1 , wherein said PMSCs express an intracellular marker comprising one or more of Nestin, Vimentin, S100β or neurofilament medium (NFM).
10. The method of claim 1 , wherein said PMSCs express a transcriptional factor comprising one or more of Sox2, Sox10, Sox17 or Slug.
11. The method of claim 1 , wherein said PMSCs lack expression of one or more endothelial markers or hematopoietic markers.
12. The method of claim 11 , wherein said marker is one or more of CD31, CD34 or CD45.
13. The method of claim 1 , wherein the conditioned media is concentrated in an amount selected from the group of at least about 5 fold; at least about 10 fold; at least about 15 fold; at least about 20 fold; at least about 25 fold; at least about 30 fold; at least about 35 fold; at least about 40 fold; at least about 45 fold; at least about 50 fold; at least about 55 fold; at least about 60 fold; at least about 65 fold; at least about 70 fold; at least about 75 fold; at least about 80 fold; at least about 85 fold; or at least about 90 fold.